A tighter archive for life-science signals.
Search once, then narrow by source or topic.
Moderna to pay up to $2.25B to end mRNA vaccine patent fight
Moderna to pay up to $2.25B to end mRNA vaccine patent fight
Moderna to pay up to $2.25B to settle COVID-19 patents case
Moderna to pay up to $2.25B to settle COVID-19 patents case
Moderna to pay up to $2.25B to settle COVID-19 patents case
Moderna to pay up to $2.25B to settle COVID-19 patents case
Moderna will pay $950M to settle Covid vaccine patent claims with Arbutus, Roivant
Moderna will pay $950M to settle Covid vaccine patent claims with Arbutus, Roivant
CHMP recommends Moderna's flu-Covid shot and Novartis pill for hives
CHMP recommends Moderna's flu-Covid shot and Novartis pill for hives
Moderna’s combination flu, COVID shot wins over European drug regulators
Moderna’s combination flu, COVID shot wins over European drug regulators
Potential Eylea competitor disappoints; FDA to review Moderna’s flu vaccine; Another rare disease rejection; and more
Potential Eylea competitor disappoints; FDA to review Moderna’s flu vaccine; Another rare disease rejection; and more
White House frustration may have fueled FDA’s Moderna walkback: Politico
White House frustration may have fueled FDA’s Moderna walkback: Politico
FDA accepts filing for Moderna flu vaccine after swift rethink
FDA accepts filing for Moderna flu vaccine after swift rethink
Reversal on Moderna's flu application follows atypical path through FDA
Reversal on Moderna's flu application follows atypical path through FDA
FDA reverses course on Moderna’s flu vaccine
FDA reverses course on Moderna’s flu vaccine
FDA reverses course, will review Moderna’s flu vaccine
FDA reverses course, will review Moderna’s flu vaccine
Moderna faces setback in Arbutus' mRNA patent fight
Moderna faces setback in Arbutus' mRNA patent fight
Moderna vs FDA; Paul Hudson out at Sanofi; Why clinical trials are so costly; and more
Moderna vs FDA; Paul Hudson out at Sanofi; Why clinical trials are so costly; and more
With the FDA's Moderna decision, vaccine makers face increasingly uncertain regulatory environment
With the FDA's Moderna decision, vaccine makers face increasingly uncertain regulatory environment
Moderna R&D spend shrunk 31% in 2025 amid major pipeline reorg
Moderna R&D spend shrunk 31% in 2025 amid major pipeline reorg
Moderna's flu shot dilemma muddies 2028 break-even guidance
Moderna's flu shot dilemma muddies 2028 break-even guidance
Moderna shares jump as company affirms growth outlook
Moderna shares jump as company affirms growth outlook
Brand directory, kept in view
A rolling strip of the companies, platforms, CROs and device makers that show up across the coverage.
Open about page